COPENHAGEN, March 3 (Reuters) - The U.S. Food and Drug Administration has approved Danish drugmaker Novo Nordisk's growth hormone injection pen Norditropin Flexpro, the company said on Wednesday.
March 5, 2010 — The US Food and Drug Administration (FDA) has approved a prefilled somatropin (rDNA origin) injection pen (Norditropin FlexPro, Novo Nordisk, Inc) for the treatment of growth hormone ...
PLAINSBORO, N.J., July 16, 2015 /PRNewswire/ -- Novo Nordisk announced today the U.S. Food and Drug Administration (FDA) approval of FlexPro® PenMate®, designed for users of Norditropin® FlexPro® 5 mg ...
Credit: Pfizer. Ngenla is expected to be available in August 2023. The Food and Drug Administration (FDA) has approved Ngenla ™ (somatrogon-ghla), a once-weekly, human growth hormone analog for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback